Enrolling By Invitation PHASE2 INTERVENTIONAL 2-arm
NCT07372781
Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease
Sponsor: Beijing Chest Hospital
Conditions
Monotherapy Mycobacterium Abscessus Infection
Interventions
Contezolid linezolid
Updated 1 time since 2026 Last updated: Jan 23, 2026 Started: Jan 1, 2026 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07372781, this PHASE2 trial focuses on Monotherapy and Mycobacterium Abscessus Infection and remains ongoing. Sponsored by Beijing Chest Hospital, it has been updated 1 time since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
1 version recorded Enrolling By Invitation — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Beijing Chest Hospital
Data source: Beijing Chest Hospital
For direct contact, visit the study record on ClinicalTrials.gov .